Advertisement Pharmaceutical Business review - Page 358 of 5284 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
August 4, 2026

Curium to acquire Lantheus in all-cash deal worth up to $8bn

CapVest Partners-backed Curium has agreed to buy rival US-based radiopharmaceutical company Lantheus in an all-cash deal worth up to nearly $8bn.

The combined entity would operate in over 70 countries, integrating Curium and Lantheus’ radiopharmaceutical operations. Credit: Dmitry Kalinovsky / Shutterstock.com.